To discuss a potential collaboration with the Center for Individualized Medicine, contact us.
Gerstner Family Career Development Awards
The Gerstner Family Foundation established the Gerstner Family Career Development Awards in Individualized Medicine, so that early career investigators receive important seed money to conduct research to predict, prevent, treat and cure disease using individualized medicine approaches.
Learn more about the Gerstner Family Career Development Awards.
In early 2013, the Center for Individualized Medicine formalized a collaboration with Silicon Valley Biosystems, which subsequently changed its name to Lifecode. The company's mission is to improve the lives of patients by providing concise, accurate and actionable molecular information.
The Center for Individualized Medicine is contributing clinical and laboratory expertise and support to Lifecode as it develops a portfolio of NGS-based cancer assays. The collaboration also includes Mayo Clinic Laboratories, Mayo's reference laboratory that provides services worldwide.
Established in 2013, start-up company Oncospire Genomics accelerates and commercializes cancer research in the Center for Individualized Medicine Biomarker Discovery Program. The company focuses on hematological and urogenital cancers, with plans to expand as discoveries are made.
Biomarkers discovered by Oncospire Genomics help provide individualized cancer care for patients at Mayo Clinic and around the world through new laboratory tests that offer more insight into how cancers progress and which medications will best treat the individual patient.
The company is an equal partnership between Mayo Clinic and Cancer Genetics, Inc., which contributes operating capital; and Mayo contributes in-kind with research laboratory services, clinical experience and leading research expertise. The collaboration also includes Mayo Clinic Laboratories, Mayo's reference laboratory that provides services worldwide for clinical validation and commercialization of new tests.
Mayo-Illinois Alliance for Technology-Based Healthcare
The Mayo-Illinois Alliance for Technology-Based Healthcare was founded in 2010 by Mayo Clinic and the University of Illinois – Urbana Champaign (UIUC) to advance research and clinical treatment options related to individualized medicine. It consists of:
- Integrated research activities focusing on information-based medicine, genomics and point-of-care diagnostics
- Entrepreneurial efforts to ensure full deployment and commercialization of educational and research outcomes
- Innovative educational programs to train the next generation of clinicians and biomedical scientists
Specific collaborative activities include:
Arizona State University
The Center for Individualized Medicine and Arizona State University (ASU) are working together on many fronts, including an initiative to jointly fund research projects that lead to commercialization opportunities. In February 2013, the first two $100,000 grants were awarded, which aided in the launch of EndoVantage.
Other collaborative activities include:
- Funding several research studies with Mayo and ASU investigators, including a biomarker discovery project focused on protein microarray signatures for the detection of colorectal cancer
- Funding a mass spectrometer for research into metallomics-related biomarkers
Translational Genomics Research Institute (TGen)
Investigators from Mayo Clinic and TGen, a Phoenix-based nonprofit research organization, have developed extensive individualized medicine-based collaborations spanning a variety of diseases, including multiple myeloma, breast cancer, melanoma, squamous cell carcinoma and pancreatic cancer.
As part of these collaborations, some Mayo and TGen researchers have received joint academic appointments at each other's organization.
Through its Information Technology Program, the Center for Individualized Medicine has joined Oracle's Strategic Development Partnership to collaborate on expanding Oracle's Translational Research Center product to centrally manage trillions of unique genetic variants for Mayo Clinic patients.
This partnership allows Mayo to provide strategic direction and influence on future functionality of the Translational Research Center solution. In addition, it allows Mayo early access to innovative technologies.
This resource will help the Center for Individualized Medicine manage genomic variants for multiplexed panels and whole-exome and whole-genome testing, leveraging the enormous amount of genomic data generated through laboratory testing of our patients. The goal is to develop a single infrastructure that can support individualized medicine activities spanning research and clinical practice, complete with privacy and security controls.
Seres Health, Enterome, Second Genome and Whole Biome
Collaborations with Seres Health (Cambridge, Massachusetts); Enterome (Paris, France); Second Genome (San Francisco, California); and Whole Biome (San Francisco, California); are accelerating discovery and translation of microbiome diagnostics and therapies for a range of diseases.
The Seres collaboration utilizes microbiological organisms as therapeutic agents for disease in clinical trials. The Enterome collaboration focuses on discovery and validation of gut microbiome-based diagnostics to predict responses to nutritional interventions in overweight and obese patients. Mayo Clinic and Second Genome collaborate in areas such as irritable bowel disease; obesity / metabolic disease; and surgery in obese patients with and without type 2 diabetes. Mayo Clinic and Whole Biome are collaborating to decrease rates of preterm birth and labor, the leading cause of infant mortality in the United States, through microbiome-based diagnostics and therapies.
Oneome is a Minneapolis-based genomics interpretation company that exports Mayo’s extensive pharmacogenomics knowledge in the form of concise and actionable reports to help providers deliver the right medication at the right time. Oneome reports focus on providing pharmacogenomically driven guidance for medications with high levels of evidence in the medical literature.
Sanguine Bioservices is a Los Angeles-based start-up that utilizes social media software for interaction and recruitment with patient advocacy groups. They are creating a unique sample collection marketplace for biopharmaceutical companies that would like access to samples in order to develop therapeutics. Sanguine is now working on expanding the platform to other applications, including home sample collection for clinical tests.